Time and dose-dependent effects of Labisia pumilaon bone oxidative status of postmenopausal osteoporosis rat model

Nadia Mohd Effendy, Ahmad Nazrun Shuid

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Postmenopausal osteoporosis can be associated with oxidative stress and deterioration of antioxidant enzymes. It ismainly treated with estrogen replacement therapy (ERT). Although effective, ERT may cause adverse effects such as breast cancer and pulmonary embolism. Labisia pumila var. alata(LP), a herb used traditionally for women's health was found to protect against estrogen-deficient osteoporosis. An extensive study was conducted in a postmenopausal osteoporosis rat model using several LP doses and duration of treatments to determine if anti-oxidative mechanisms were involved in its bone protective effects. Ninety-six female Sprague-Dawley rats were randomly divided into six groups; baseline group (BL), sham-operated (Sham), ovariectomised control (OVXC), ovariectomised (OVX) and given 64.5 μg/kg of Premarin (ERT), ovariectomised and given 20 mg/kg of LP (LP20) and ovariectomised and given 100 mg/kg of LP (LP100). The groups were further subdivided to receive their respective treatments via daily oral gavages for three, six or nine weeks of treatment periods. Following euthanization, the femora were dissected out for bone oxidative measurementswhich include superoxide dismutase (SOD), glutathione peroxidase (GPx) and malondialdehyde (MDA) levels. Results: The SOD levels of the sham-operated and all the treatment groups were significantly higher than the OVX groups at all treatment periods. The GPx level of ERT and LP100 groups at the 9th weekof treatment were significantly higher thanthe baseline and OVX groups. MDA level of the OVX group was significantlyhigher than all the other groups at weeks 6 and 9. The LP20 and LP100 groups at the 9th week of treatment had significantly lower MDA levels than the ERT group. There were no significant differences between LP20 and LP100 for all parameters. Thus, LP supplementations at both doses, which showed the best results at 9 weeks, may reduce oxidative stress which in turn may prevent bone loss via its anti-oxidative property.

Original languageEnglish
Pages (from-to)3288-3302
Number of pages15
JournalNutrients
Volume6
Issue number8
DOIs
Publication statusPublished - 21 Aug 2014

Fingerprint

estrogen replacement therapy
Postmenopausal Osteoporosis
osteoporosis
Estrogen Replacement Therapy
animal models
bones
Bone and Bones
malondialdehyde
dosage
Malondialdehyde
glutathione peroxidase
superoxide dismutase
conjugated estrogens
oxidative stress
Glutathione Peroxidase
women's health
Therapeutics
Superoxide Dismutase
embolism
Oxidative Stress

Keywords

  • Antioxidant
  • Estrogen
  • Labisia pumila
  • Menopause
  • Osteoporosis

ASJC Scopus subject areas

  • Food Science
  • Medicine(all)

Cite this

Time and dose-dependent effects of Labisia pumilaon bone oxidative status of postmenopausal osteoporosis rat model. / Effendy, Nadia Mohd; Shuid, Ahmad Nazrun.

In: Nutrients, Vol. 6, No. 8, 21.08.2014, p. 3288-3302.

Research output: Contribution to journalArticle

@article{118cb711e276458eb530727116ff82f3,
title = "Time and dose-dependent effects of Labisia pumilaon bone oxidative status of postmenopausal osteoporosis rat model",
abstract = "Postmenopausal osteoporosis can be associated with oxidative stress and deterioration of antioxidant enzymes. It ismainly treated with estrogen replacement therapy (ERT). Although effective, ERT may cause adverse effects such as breast cancer and pulmonary embolism. Labisia pumila var. alata(LP), a herb used traditionally for women's health was found to protect against estrogen-deficient osteoporosis. An extensive study was conducted in a postmenopausal osteoporosis rat model using several LP doses and duration of treatments to determine if anti-oxidative mechanisms were involved in its bone protective effects. Ninety-six female Sprague-Dawley rats were randomly divided into six groups; baseline group (BL), sham-operated (Sham), ovariectomised control (OVXC), ovariectomised (OVX) and given 64.5 μg/kg of Premarin (ERT), ovariectomised and given 20 mg/kg of LP (LP20) and ovariectomised and given 100 mg/kg of LP (LP100). The groups were further subdivided to receive their respective treatments via daily oral gavages for three, six or nine weeks of treatment periods. Following euthanization, the femora were dissected out for bone oxidative measurementswhich include superoxide dismutase (SOD), glutathione peroxidase (GPx) and malondialdehyde (MDA) levels. Results: The SOD levels of the sham-operated and all the treatment groups were significantly higher than the OVX groups at all treatment periods. The GPx level of ERT and LP100 groups at the 9th weekof treatment were significantly higher thanthe baseline and OVX groups. MDA level of the OVX group was significantlyhigher than all the other groups at weeks 6 and 9. The LP20 and LP100 groups at the 9th week of treatment had significantly lower MDA levels than the ERT group. There were no significant differences between LP20 and LP100 for all parameters. Thus, LP supplementations at both doses, which showed the best results at 9 weeks, may reduce oxidative stress which in turn may prevent bone loss via its anti-oxidative property.",
keywords = "Antioxidant, Estrogen, Labisia pumila, Menopause, Osteoporosis",
author = "Effendy, {Nadia Mohd} and Shuid, {Ahmad Nazrun}",
year = "2014",
month = "8",
day = "21",
doi = "10.3390/nu6083288",
language = "English",
volume = "6",
pages = "3288--3302",
journal = "Nutrients",
issn = "2072-6643",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Time and dose-dependent effects of Labisia pumilaon bone oxidative status of postmenopausal osteoporosis rat model

AU - Effendy, Nadia Mohd

AU - Shuid, Ahmad Nazrun

PY - 2014/8/21

Y1 - 2014/8/21

N2 - Postmenopausal osteoporosis can be associated with oxidative stress and deterioration of antioxidant enzymes. It ismainly treated with estrogen replacement therapy (ERT). Although effective, ERT may cause adverse effects such as breast cancer and pulmonary embolism. Labisia pumila var. alata(LP), a herb used traditionally for women's health was found to protect against estrogen-deficient osteoporosis. An extensive study was conducted in a postmenopausal osteoporosis rat model using several LP doses and duration of treatments to determine if anti-oxidative mechanisms were involved in its bone protective effects. Ninety-six female Sprague-Dawley rats were randomly divided into six groups; baseline group (BL), sham-operated (Sham), ovariectomised control (OVXC), ovariectomised (OVX) and given 64.5 μg/kg of Premarin (ERT), ovariectomised and given 20 mg/kg of LP (LP20) and ovariectomised and given 100 mg/kg of LP (LP100). The groups were further subdivided to receive their respective treatments via daily oral gavages for three, six or nine weeks of treatment periods. Following euthanization, the femora were dissected out for bone oxidative measurementswhich include superoxide dismutase (SOD), glutathione peroxidase (GPx) and malondialdehyde (MDA) levels. Results: The SOD levels of the sham-operated and all the treatment groups were significantly higher than the OVX groups at all treatment periods. The GPx level of ERT and LP100 groups at the 9th weekof treatment were significantly higher thanthe baseline and OVX groups. MDA level of the OVX group was significantlyhigher than all the other groups at weeks 6 and 9. The LP20 and LP100 groups at the 9th week of treatment had significantly lower MDA levels than the ERT group. There were no significant differences between LP20 and LP100 for all parameters. Thus, LP supplementations at both doses, which showed the best results at 9 weeks, may reduce oxidative stress which in turn may prevent bone loss via its anti-oxidative property.

AB - Postmenopausal osteoporosis can be associated with oxidative stress and deterioration of antioxidant enzymes. It ismainly treated with estrogen replacement therapy (ERT). Although effective, ERT may cause adverse effects such as breast cancer and pulmonary embolism. Labisia pumila var. alata(LP), a herb used traditionally for women's health was found to protect against estrogen-deficient osteoporosis. An extensive study was conducted in a postmenopausal osteoporosis rat model using several LP doses and duration of treatments to determine if anti-oxidative mechanisms were involved in its bone protective effects. Ninety-six female Sprague-Dawley rats were randomly divided into six groups; baseline group (BL), sham-operated (Sham), ovariectomised control (OVXC), ovariectomised (OVX) and given 64.5 μg/kg of Premarin (ERT), ovariectomised and given 20 mg/kg of LP (LP20) and ovariectomised and given 100 mg/kg of LP (LP100). The groups were further subdivided to receive their respective treatments via daily oral gavages for three, six or nine weeks of treatment periods. Following euthanization, the femora were dissected out for bone oxidative measurementswhich include superoxide dismutase (SOD), glutathione peroxidase (GPx) and malondialdehyde (MDA) levels. Results: The SOD levels of the sham-operated and all the treatment groups were significantly higher than the OVX groups at all treatment periods. The GPx level of ERT and LP100 groups at the 9th weekof treatment were significantly higher thanthe baseline and OVX groups. MDA level of the OVX group was significantlyhigher than all the other groups at weeks 6 and 9. The LP20 and LP100 groups at the 9th week of treatment had significantly lower MDA levels than the ERT group. There were no significant differences between LP20 and LP100 for all parameters. Thus, LP supplementations at both doses, which showed the best results at 9 weeks, may reduce oxidative stress which in turn may prevent bone loss via its anti-oxidative property.

KW - Antioxidant

KW - Estrogen

KW - Labisia pumila

KW - Menopause

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84927173529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927173529&partnerID=8YFLogxK

U2 - 10.3390/nu6083288

DO - 10.3390/nu6083288

M3 - Article

C2 - 25195641

AN - SCOPUS:84927173529

VL - 6

SP - 3288

EP - 3302

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 8

ER -